Elmiron (Pentosan Polysulfate Sodium)

The Elmiron (pentosan polysulfate sodium) docket, built on claims that long-term use of this interstitial cystitis medication is associated with a distinctive retinal condition known as pigmentary maculopathy that can cause permanent vision impairment, carries 286 pending actions roughly six years after centralization. This is a chronic-use drug injury with a long latency profile — patients typically took the medication for years before developing detectable retinal changes — which shapes both the claims population's growth pattern and the evidentiary record available for underwriting.

For a funder, the central diligence questions in this docket are duration of use and severity of retinal injury: claims involving many years of Elmiron use with confirmed maculopathy findings on retinal imaging present a different causation and damages profile than claims with shorter use histories or earlier-stage findings. Ophthalmologic diagnostic evidence — retinal imaging and visual-field testing — plays an unusually central evidentiary role in this docket relative to many other drug-injury mass torts.

Medical-lien considerations are relevant primarily around diagnostic and ongoing ophthalmologic monitoring costs rather than surgical intervention, since there is no established surgical remedy for this specific retinal condition, which is a distinct lien profile from a device-related mass tort involving revision surgery.

Inventory finance against a meaningful book of Elmiron claims can work for a firm with real volume, with underwriting segmented by duration of use and diagnostic severity rather than treated as a uniform population, given how much those two variables drive individual claim strength. A firm-capital facility built around a broader interstitial-cystitis practice group can also make sense where a firm's Elmiron inventory sits alongside other related intake, since the underlying diagnostic workflow and referral relationships tend to overlap.

Criterica Capital's mass-tort finance line applies to claims in this docket, and Criterica Intelligence's structural brief covers the duration-of-use and diagnostic-severity factors shaping claim variation in more depth.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.